Kestra Medical Technologies, Ltd. 12-Month Price Target Raised to $31.12
Analysts have increased the average 12-month price target for Kestra Medical Technologies, Ltd. stock to $31.12, reflecting an implied upside of approximately 8%.
Stocks · News reference
Kestra Medical Technologies has published primary results from the ASSURE WCD Clinical Evaluation Post-Approval Study (ACE-PAS), the largest prospective real-world study of wearable cardioverter defibrillators to date.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Analysts have increased the average 12-month price target for Kestra Medical Technologies, Ltd. stock to $31.12, reflecting an implied upside of approximately 8%.
Timothy P. Moran filed a Form 4 with the SEC regarding Kestra Medical Technologies, Ltd. on November 5, 2026.
An insider at Kestra Medical Technologies, Ltd. sold shares of the company's common stock valued at approximately $2.4 million, as disclosed in a recent SEC filing.
Kestra Medical Technologies, Ltd. announced its scheduled participation in upcoming investor conferences.
Traci S. Umberger, Director, General Counsel and Chief Administrative Officer of Kestra Medical Technologies, sold 100,000 shares of company stock on October 21, 2026.
Brian Daniel Webster, President and CEO of Kestra Medical Technologies, sold 15,000 shares of the company's stock on October 20, 2026.